EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES New data to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April) shows that participants taking the new anti-COVID drug molnupiravir eliminate actively infectious SARS-CoV-2 virus by day 3 of starting therapy, while many participants who received placebo...
Tag: <span>COVID antiviral drug</span>
Post
New analysis of investigational COVID antiviral drug molnupiravir shows it appears to clear virus equally well in immunocompromised patients and those who are immunocompetent
EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES A new analysis of data on the ‘COVID-19 pill’ molnupiravir shows it appears to clear active SARS-CoV-2 virus equally well in immunocompromised patients and those who are immunocompetent. The analysis, which will be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022,...